Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 for Intraoperative Imaging of Pituitary Adenoma
NCT02629549Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2015
- Primary completion
- Aug 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pafolacianine in pituitary adenoma, sponsored by University of Pennsylvania. Primary endpoints: Detection of OTL38 in tumor tissue at 60 months and Ability of OTL38 to discern between tumorous tissue and normal, neural tissue at 60 months. Started Oct 2015; status: terminated.
02
Drugs
pafolacianine
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on NCT02629549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629549.